Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib-based GVHD Prophylaxis in Myeloablative Allogeneic HSCT
NCT01323920Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 2011
- Primary completion
- Feb 2013
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in graft-versus-host disease (GVHD), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Cumulative Incidence of Grade II-IV Acute GVHD at 100 days. Started May 2011; status: completed.
02
Drugs
bortezomib
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT01323920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01323920.